News
InvestorsHub on MSN1d
Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion AcquisitionShares of Blueprint Medicines Corp. (NASDAQ:BPMC) soared 26.5% after Sanofi (NASDAQ:SNY) revealed plans to acquire the ...
We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...
The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical ...
InvestorsHub on MSN1d
Sanofi to Acquire Blueprint Medicines for $9.1 BillionSanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases.
Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...
Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil Neuroscience Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common ...
Sanofi will buy the US maker of the world’s only approved treatment for a debilitating rare blood disorder for up to $9.5bn, as it seeks to boost its immunology medicine pipeline.
Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback